All posts by CAC2

CAC2 Webinar–What is a Pediatric Study Plan?

May 27, 2020
Webinars No comments yet
Our May CAC2 All-Member webinar focused on how pediatric cancer study plans are developed.  CAC2 Member Kelli Wright (CureSearch) introduced Dr. Brenda Weigel from University of Minnesota’s Masonic Cancer Center and Dr. Samuel Blackman of Day One Biopharmaceuticals as they addressed: What is a Pediatric Study Plan (PSP)? How is it created and by who? How does FDARA/RACE for Children impact PSP development? Where in the process are the opportunities to create better PSPs? Currently, regulatory agencies require that a pharmaceutical or biotechnology company submit a Pediatric Study Plan (PSP) to confirm the suitability of drug usage in the pediatric [...] Read more

Day One Biopharmaceuticals

May 21, 2020
Community News No comments yet

Day One Biopharmaceutical, a start-up biotech company founded with a focus on developing therapies for children with cancer through drug repurposing announced its debut in the market last week.  Its first agent, DAY101, licensed from Takeda Pharmaceuticals, is a targeted treatment for children with low grade glioma, a type of brain cancer. DAY101 is a Phase 2-ready RAF inhibitor that also shows strong potential for other pediatric and adult indications. The company is co-founded by Chief Medical Officer Dr. Sam Blackman (who offered our May webinar) and Acting CEO Julie Grant from Canaan Partners.   You can read more here.   Please look for a […]

Read more

Phase III Pediatric Brain Tumor Clinical Trial Collaboration

May 3, 2020
Collaborative Achievements No comments yet
Everybody is worried these days.  We have witnessed toilet paper hoarding and other behaviors that make us feel vulnerable and alone.  That's why we would like to hold up and highlight some fabulous Member Collaborations.   One recent collaboration between two CAC2 members really brings this story of hope in the midst of worry during Coronavirus as these two organizations, The Taylor Matthews Foundation and the Pediatric Brain Tumor Foundation found a way to support funding for a Phase III clinical trial. Here's the story in their words: "As you may recall, The Taylor Matthews Foundation first linked arms with PBTF [...] Read more

Joint Webinar Presentation: The Pandemic’s Impact on the Pediatric Cancer Research Landscape

April 28, 2020
Collaborative Achievements No comments yet

Solving Kids’ Cancer and Max Cure Foundation offered a joint webinar: The Pandemic’s Impact on the Pediatric Cancer Research Landscape Timothy P. Cripe, Chief of Hematology and Oncology at Nationwide Children’s Hospital moderated the session that featured an all-star line-up: Peter Adamson, MD – former Chair, Children’s Oncology Group (COG) and current Global Head, Oncology Development & Pediatric Innovation, Sanofi Mark Kieran, MD, PhD – Pediatric Clinical Trial Lead, Bristol Myers Squibb Jeffery J. Auletta, MD – Director of the Blood and Marrow Transplant (BMT) Program and the Host Defense and Immunocompromised Infectious Diseases Program at Nationwide Children’s Hospital. Carol Thiele, Ph.D, […]

Read more

CAC2 Member Guide to Navigating Covid19

April 1, 2020
CAC2 News No comments yet
If you want to know what the $2.2 trillion CARES Act economic relief package means for nonprofits, donors, and individuals, have asked yourself "what can I do?" want to brush up your leadership skills or explore ideas to help with fundraising in a crisis, or just need accurate and reliable information, then the CAC2 Member Guide to Navigating the Covid-19 crisis may help.  Members have worked together to build this document to help organizational and individual members during this unprecedented crisis.     If we have overlooked an essential resource, let us know here:  Suggest a Resource for the Guide.   You [...] Read more

Members Help Each Other Spread the Word to Families During the Pandemic

March 25, 2020
Collaborative Achievements No comments yet

CAC2 Members Greg Aune, Max Cure Foundation, and Solving Kids Cancer helped to bring answers to a community in turmoil over the Covid 19 crisis by co-promoting each others’ webinars to get information into more people’s hands: Dr. Gregory Aune “COVID-19: Addressing Family Concerns for Children with Cancer and Survivors” Dr. Timothy Cripe “Latest COVID-19 Insights from Doctors + Stories from the Frontline to inform Childhood Cancer Families & the General Community” Ryan Norton “Stress, Anxiety and Coping with COVID-19: A Conversation for Families in the Childhood Cancer Community”

Read more

Guest Blog–Kids First Second Chance: Engaging the Community in Fostering Pediatric Genomics Research

March 2, 2020
Blog Posts, Guest Blogs No comments yet
By Guest blogger Valerie Cotton, Kids First Program Manager, NICHD Childhood cancers and structural birth defects have profound, lifelong effects on children and their families. Birth defects are the leading cause of death in the first year of life, and cancer remains the leading cause of childhood disease-related mortality beyond the first year of life, according to the Centers for Disease Control and Prevention. Moreover, a child born with a birth defect is at a higher risk for childhood cancer, suggesting these conditions may be caused by shared genetic pathways. However, limited data and resources are available to investigate potential genetic [...] Read more

CAC2 Member Blog–#Moonshot4Kids

March 1, 2020
Blog Posts, Member Blogs No comments yet
By CAC2 Member Janet Demeter, Jack's Angels Did you know that brain cancer is the leading cause of death in children with cancer?  It’s also one of the least-funded areas of cancer research.  DIPG, diffuse intrinsic pontine glioma, is perhaps the deadliest of them all.  The experience of DIPG is a terrible wake-up call:   with no viable solutions, the discovery that profits and numbers count more than the value of your child’s life, DIPG exemplifies in a profound way the experience that so many children with cancer and their families endure–to watch their children die in utter helplessness. We would [...] Read more
Archives

Enquire now

Give us a call or fill in the form below and we will contact you. We endeavor to answer all inquiries within 24 hours on business days.